Description

BSE announces the listing of 300 units of Commercial Paper issued by VIVRITI CAPITAL LIMITED on private placement basis, with a face value of Rs. 5,00,000 each, maturing on February 25, 2026.

Summary

BSE has listed new Commercial Paper issued by VIVRITI CAPITAL LIMITED on private placement basis. The listing comprises 300 units with a face value of Rs. 5,00,000 each, rated CARE A1+. The securities are available for trading on the BSE Debt segment with effect from November 10, 2025. The Federal Bank Ltd serves as the Issuing and Paying Agent.

Key Points

  • Security Type: Commercial Paper (Private Placement)
  • Quantity: 300 units
  • Face Value: Rs. 5,00,000 per unit
  • Issue Price: Rs. 4,86,340 per unit
  • Market Lot: 1 unit
  • Scrip Code: 730520
  • Scrip ID: VCL71125
  • ISIN: INE01HV14AE3
  • Credit Rating: CARE A1+
  • Trading: Dematerialized form only
  • Standard Denomination: Rs. 5 Lakhs and multiples thereof
  • Tick Size: 1 paise

Regulatory Changes

No regulatory changes introduced. This is a standard listing notification.

Compliance Requirements

  • Trading members must trade these securities only in dematerialized form under ISIN INE01HV14AE3
  • Trading shall take place in standard denomination of Rs. 5 Lakhs and multiples thereof
  • Members requiring clarification may contact the debt department on specified phone numbers (22728352/8597/8995/5753/8915)

Important Dates

  • Allotment Date: November 7, 2025
  • Listing Date: November 10, 2025
  • Redemption Date: February 25, 2026

Impact Assessment

Minimal market impact. This is a routine debt instrument listing on the BSE Debt segment. The commercial paper provides short-term financing for VIVRITI CAPITAL LIMITED with a maturity period of approximately 110 days. The CARE A1+ rating indicates adequate safety regarding timely payment of financial obligations. Trading is restricted to institutional and high-net-worth investors given the Rs. 5 lakh minimum denomination requirement.

Impact Justification

Routine commercial paper listing notification with no impact on equity markets or broad regulatory changes